Letter/Comment
The latest advocacy letters and comments from the 黑料正能量 Association.
AHA comments on the Centers for Medicare & Medicaid Services鈥 advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs.
The AHA and Federation of 黑料正能量s 鈥渟trongly believe that any public policy solution to resolve surprise bills must protect patients by prohibiting balance billing and by limiting patients鈥 cost-sharing to an in-network amount,鈥 the organizations Dec. 21 told members of Congress.
AHA's comments on the proposed rule from the Departments of the Treasury, Labor and Health and Human Services that would change how employers may use health
reimbursement arrangements (HRAs) to help employees finance health care
coverage
AHA comments on the Centers for Medicare & Medicaid Services (CMS) proposed rule that would set forth policy changes for the 2020 and 2021 Medicare Advantage (MA) plan years.
AHA comments on the guidance modifying the regulations governing waivers under Section 1332 of the Affordable Care Act.
AHA expresses concerns about the recent Department of Health and Human Services OIG audit report.
The AHA voiced support for a Centers for Medicare & Medicaid Services鈥 proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to 鈥渞ein in skyrocketing drug prices鈥 for patients and the providers who serve them. 鈥淲e appreciate CMS鈥欌
The Federal Trade Commission鈥檚 approach to reviewing hospital mergers 鈥渋s overbroad, does not properly credit the many pro-consumer benefits of hospital transactions, and ignores key realities of the marketplace,鈥 according to an analysis submitted to the agency for a series of FTC hearings on鈥
AHA letter to Speaker Ryan and Minority Leader Pelosi expressing strong support for House passage of H.R.1318, the Preventing Maternal Deaths Act.
AHA comments on the National Committee on Vital and Health Statistics鈥 draft recommendations for the predictability roadmap.